TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight

Benzinga Logo Benzinga By Vandana Singh
Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight

Eli Lilly announced positive Phase 3b trial results for TOGETHER-PsA, showing that combining Taltz (ixekizumab) with Zepbound (tirzepatide) significantly outperforms Taltz alone in treating psoriatic arthritis and obesity. The dual treatment achieved a 31.7% improvement rate versus 0.8% for monotherapy, with a 64% relative increase in ACR50 response rates. Adverse events were mild to moderate and consistent with known safety profiles.

Insights
LLY   positive

The company announced successful Phase 3b trial results demonstrating superior efficacy of its dual-drug combination therapy for psoriatic arthritis and obesity. The study met primary and key secondary endpoints with strong clinical outcomes (31.7% vs 0.8% improvement rates) and favorable safety profiles. Stock was up 0.72% in premarket trading and approaching 52-week highs.